Z
3.66
-0.21 (-5.43%)
| Previous Close | 3.87 |
| Open | 3.85 |
| Volume | 990,021 |
| Avg. Volume (3M) | 2,011,422 |
| Market Cap | 260,542,048 |
| Price / Sales | 7.13 |
| Price / Book | 1.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -746.40% |
| Diluted EPS (TTM) | -3.14 |
| Total Debt/Equity (MRQ) | 14.27% |
| Current Ratio (MRQ) | 6.94 |
| Operating Cash Flow (TTM) | -151.52 M |
| Levered Free Cash Flow (TTM) | -79.27 M |
| Return on Assets (TTM) | -26.62% |
| Return on Equity (TTM) | -59.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Zentalis Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.80 |
|
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.58% |
| % Held by Institutions | 80.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ishara Investments Lp | 31 Mar 2026 | 1,230,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JOHNSON DAVID MICHAEL | 3.52 | - | 57,100 | 200,992 |
| KARIUKI ENOCH | 3.52 | - | 57,100 | 200,992 |
| MYERS SCOTT DUNSETH | 3.52 | - | 57,100 | 200,992 |
| SKVARKA JAN | 3.52 | - | 57,100 | 200,992 |
| WALKER LUKE NATHANIEL | 3.52 | - | 57,100 | 200,992 |
| Aggregate Net Quantity | 285,500 | |||
| Aggregate Net Value ($) | 1,004,960 | |||
| Aggregate Avg. Buy ($) | 3.52 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MYERS SCOTT DUNSETH | Director | 16 Jun 2026 | Acquired (+) | 57,100 | 3.52 | 200,992 |
| KARIUKI ENOCH | Director | 16 Jun 2026 | Acquired (+) | 57,100 | 3.52 | 200,992 |
| WALKER LUKE NATHANIEL | Director | 16 Jun 2026 | Acquired (+) | 57,100 | 3.52 | 200,992 |
| SKVARKA JAN | Director | 16 Jun 2026 | Acquired (+) | 57,100 | 3.52 | 200,992 |
| JOHNSON DAVID MICHAEL | Director | 16 Jun 2026 | Acquired (+) | 57,100 | 3.52 | 200,992 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |